News Related to Nab-paclitaxel

Related coverage linked through entity extraction aliases.

FDA Approves Optune Pax Device for Locally Advanced Pancreatic Cancer

Feb 13, 2026

The FDA has approved Optune Pax, a wearable device delivering tumor treating fields for locally advanced pancreatic cancer. The approval marks the first new treatment modality for this indication in nearly 30 years.

FDA Approves Optune Pax for Locally Advanced Pancreatic Cancer, First New Treatment in Decades

Feb 13, 2026

The FDA approved Novocure's Optune Pax device for locally advanced pancreatic cancer treatment alongside chemotherapy, marking the first new treatment option in this indication since 1996. Phase III trial data showed statistically significant survival improvement.